Very pleasing indeed but at the same time it's very much warranted given the positive indications of PromarkerD in Janssen's first clinical study.
I think the key for Richard is securing the right distribution partner instead of investment in marketing resources. Given no indication of a US partner since the Prism Health deal collapsed, my guess, as many other long term holders also believe to be the case, is that Janssen will take exclusive distribution rights post positive results from the second phase of their study.
Plenty of news yet to come.
Hope everyone is safe and well.
Cheers
Ann: PromarkerD Intellectual Property portfolio expands, page-49
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
62.0¢ |
Change
-0.010(1.59%) |
Mkt cap ! $81.22M | |||
| Open | High | Low | Value | Volume |
| 63.0¢ | 63.0¢ | 55.0¢ | $571.7K | 964.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 59.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 62.0¢ | 9013 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |